Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 3
1981 75
1982 44
1983 169
1984 159
1985 182
1986 212
1987 181
1988 172
1989 231
1990 182
1991 199
1992 185
1993 184
1994 199
1995 228
1996 231
1997 215
1998 263
1999 243
2000 265
2001 258
2002 227
2003 246
2004 259
2005 268
2006 262
2007 256
2008 281
2009 280
2010 302
2011 296
2012 334
2013 346
2014 372
2015 410
2016 442
2017 438
2018 517
2019 545
2020 653
2021 783
2022 849
2023 777
2024 214

Text availability

Article attribute

Article type

Publication date

Search Results

12,581 results

Results by year

Filters applied: . Clear all
Page 1
Resistance to ceftazidime-avibactam and underlying mechanisms.
Wang Y, Wang J, Wang R, Cai Y. Wang Y, et al. J Glob Antimicrob Resist. 2020 Sep;22:18-27. doi: 10.1016/j.jgar.2019.12.009. Epub 2019 Dec 19. J Glob Antimicrob Resist. 2020. PMID: 31863899 Free article. Review.
OBJECTIVE: Ceftazidime-avibactam (CAZ-AVI) is a novel synthetic beta-lactamase inhibitor combination. ...
OBJECTIVE: Ceftazidime-avibactam (CAZ-AVI) is a novel synthetic beta-lactamase inhibitor combination. ...
Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.
Zhen S, Wang H, Feng S. Zhen S, et al. Infection. 2022 Dec;50(6):1409-1423. doi: 10.1007/s15010-022-01876-x. Epub 2022 Jul 4. Infection. 2022. PMID: 35781869 Review.
PURPOSE: Multidrug-resistant Gram-negative bacteria (MDR-GNB) have become a major global public health threat. Ceftazidime-avibactam (CAZ-AVI) is a newer combination of beta-lactam/beta-lactamase inhibitor, with activity against carbapenem-resistant Enterobacterales (CRE) …
PURPOSE: Multidrug-resistant Gram-negative bacteria (MDR-GNB) have become a major global public health threat. Ceftazidime-avibactam …
Ceftazidime review.
Yost RL, Ramphal R. Yost RL, et al. Drug Intell Clin Pharm. 1985 Jul-Aug;19(7-8):509-13. doi: 10.1177/106002808501900701. Drug Intell Clin Pharm. 1985. PMID: 3896712 Review.
The chemistry, in vitro activity, adverse effects, and clinical indications for the new third-generation cephalosporin, ceftazidime, are reviewed. Ceftazidime appears to have a unique place among the third-generation agents in the treatment of some infectious proces …
The chemistry, in vitro activity, adverse effects, and clinical indications for the new third-generation cephalosporin, ceftazidime, …
The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment.
Nichols WW, Bradford PA, Stone GG. Nichols WW, et al. J Antimicrob Chemother. 2023 Apr 3;78(4):871-892. doi: 10.1093/jac/dkad049. J Antimicrob Chemother. 2023. PMID: 36883356 Review.
Uncontrolled case studies over a wide range of patients infected by antibiotic multiresistant Gram-negative bacteria have demonstrated that ceftazidime/avibactam can elicit microbiological clearance of ceftazidime/avibactam-susceptible strains. In case studies where …
Uncontrolled case studies over a wide range of patients infected by antibiotic multiresistant Gram-negative bacteria have demonstrated that …
The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD).
Nichols WW, Bradford PA, Stone GG. Nichols WW, et al. J Antimicrob Chemother. 2022 Aug 25;77(9):2341-2352. doi: 10.1093/jac/dkac172. J Antimicrob Chemother. 2022. PMID: 35660869 Review.
(J Antimicrob Chemother 2022; 77: 2321-40). Avibactam protected ceftazidime in animal models of infection with ceftazidime-resistant, beta-lactamase-producing bacteria. ...In a rat abdominal abscess model, therapy with ceftazidime or ceftazidime/avibac …
(J Antimicrob Chemother 2022; 77: 2321-40). Avibactam protected ceftazidime in animal models of infection with ceftazidime-res …
Ceftazidime for respiratory infections.
Choi SH, Koh Y. Choi SH, et al. Expert Opin Pharmacother. 2012 Oct;13(14):2097-109. doi: 10.1517/14656566.2012.721777. Epub 2012 Sep 4. Expert Opin Pharmacother. 2012. PMID: 22943280 Review.
INTRODUCTION: Ceftazidime is a third-generation cephalosporin that has activity against Gram-negative bacilli, including Pseudomonas aeruginosa. The increasing prevalence of antimicrobial resistance and the limited number of antimicrobial agents in development have necessi …
INTRODUCTION: Ceftazidime is a third-generation cephalosporin that has activity against Gram-negative bacilli, including Pseudomonas …
Ceftazidime/Avibactam: Who Says You Can't Teach an Old Drug New Tricks?
Barber KE, Ortwine JK, Akins RL. Barber KE, et al. J Pharm Pharm Sci. 2016 Oct-Dec;19(4):448-464. doi: 10.18433/J3X31R. J Pharm Pharm Sci. 2016. PMID: 28057163 Free article. Review.
The US package insert for ceftazidime/avibactam (02/2015) and European public assessment report (06/2016) were also reviewed. ...Ceftazidime/avibactam was well-tolerated but does require renal adjustments. ...
The US package insert for ceftazidime/avibactam (02/2015) and European public assessment report (06/2016) were also reviewed. ...C
Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination.
Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA. Zhanel GG, et al. Drugs. 2013 Feb;73(2):159-77. doi: 10.1007/s40265-013-0013-7. Drugs. 2013. PMID: 23371303 Review.
The mean volume of distribution and half-life of 22 L (~0.3 L/kg) and ~2 hours, respectively, are similar to ceftazidime. Like ceftazidime, avibactam is primarily renally excreted, and clearance correlates with creatinine clearance. ...The exact roles for ceftazi
The mean volume of distribution and half-life of 22 L (~0.3 L/kg) and ~2 hours, respectively, are similar to ceftazidime. Like cef
Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
Mawal Y, Critchley IA, Riccobene TA, Talley AK. Mawal Y, et al. Expert Rev Clin Pharmacol. 2015;8(6):691-707. doi: 10.1586/17512433.2015.1090874. Epub 2015 Sep 30. Expert Rev Clin Pharmacol. 2015. PMID: 26420166 Review.
Treatment of complicated urinary tract infections and complicated intra-abdominal infections is increasingly difficult due to the rising prevalence of multidrug-resistant Gram-negative bacteria. Ceftazidime-avibactam is a combination of the established third-generation cep …
Treatment of complicated urinary tract infections and complicated intra-abdominal infections is increasingly difficult due to the rising pre …
Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature.
Meschiari M, Franconi I, Bacca E, Bianco V, Orlando G, Cuomo G, Bedini A, Mussini C. Meschiari M, et al. Infection. 2021 Jun;49(3):549-553. doi: 10.1007/s15010-020-01539-9. Epub 2020 Oct 19. Infection. 2021. PMID: 33074365 Free PMC article. Review.
We describe one nosocomial meningitis and two cervical osteomyelitis due to an XDR-PA who were treated with ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T) and review the literature. ...
We describe one nosocomial meningitis and two cervical osteomyelitis due to an XDR-PA who were treated with ceftazidime/avibactam (CZ …
12,581 results
You have reached the last available page of results. Please see the User Guide for more information.